GoAI
Get started
InMed Pharmaceuticals Inc. logo

InMed Pharmaceuticals Inc.

INM

NASDAQHealthcareBiotechnology

Open in GoAI

Regular session

$1.46

$0.00 · 0.00%

Aug 24, 12:24 PM ET

INM company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Hold

Wait — insufficient conviction to act

Valuation

41

Fair Value

Momentum

58

Neutral

Sentiment

67

Bullish

Risk resilience

40

Elevated Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Industry
Biotechnology
Sector
Healthcare
Headquarters
CA

Market position

Day range

Current $1.46

52-week range

Current $1.46

Open
$1.48
Previous close
$1.46
Volume
131.36K
Market cap
2.64M USD
50-day average
$1.5442
-5.45% below average
200-day average
$1.1941
+22.26% above average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
-10.91M USD
P/E (TTM)
-0×
P/B (TTM)
0.86×
P/S (TTM)
0.66×
EV / EBITDA
1.5×
Earnings yield
-257.32%
Free cash flow yield
-244.86%
Dividend yield
0.00%

Profitability & efficiency

Gross margin
30.44%
Operating margin
-246.78%
Net margin
-246.41%
Return on equity
-44.59%
Return on assets
-38.45%
Return on invested capital
-41.00%

Financial health

Debt / equity
0.06×
Current ratio
6.99×
Altman Z-score
-20.5
Piotroski F-score
1 of 9

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends226%-477%-1180%-1883%Gross margin, FY2022: 49.89%Gross margin, FY2023: 33.93%Gross margin, FY2024: 23.94%Gross margin, FY2025: 34.53%Operating margin, FY2022: -1265.95%Operating margin, FY2023: -202.60%Operating margin, FY2024: -176.92%Operating margin, FY2025: -160.20%Net margin, FY2022: -1707.32%Net margin, FY2023: -192.18%Net margin, FY2024: -166.94%Net margin, FY2025: -165.14%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2022 49.89%. Gross margin FY2023 33.93%. Gross margin FY2024 23.94%. Gross margin FY2025 34.53%. Operating margin FY2022 -1265.95%. Operating margin FY2023 -202.60%. Operating margin FY2024 -176.92%. Operating margin FY2025 -160.20%. Net margin FY2022 -1707.32%. Net margin FY2023 -192.18%. Net margin FY2024 -166.94%. Net margin FY2025 -165.14%.

Income trends

Revenue

4.94M USD+7.50%

Operating income

−7.92M USD+2.66%

Net income

−8.16M USD-6.34%
Income trends across reported periods7.3M USD−2.12M USD−11.54M USD−20.95M USDRevenue, FY2022: 1.09M USDRevenue, FY2023: 4.14M USDRevenue, FY2024: 4.6M USDRevenue, FY2025: 4.94M USDOperating income, FY2021: −12.17M USDOperating income, FY2022: −13.79M USDOperating income, FY2023: −8.38M USDOperating income, FY2024: −8.13M USDOperating income, FY2025: −7.92M USDNet income, FY2021: −12.65M USDNet income, FY2022: −18.6M USDNet income, FY2023: −7.95M USDNet income, FY2024: −7.68M USDNet income, FY2025: −8.16M USDFY2021FY2022FY2023FY2024FY2025
Revenue FY2022 1.09M USD. Revenue FY2023 4.14M USD. Revenue FY2024 4.6M USD. Revenue FY2025 4.94M USD. Operating income FY2021 −12.17M USD. Operating income FY2022 −13.79M USD. Operating income FY2023 −8.38M USD. Operating income FY2024 −8.13M USD. Operating income FY2025 −7.92M USD. Net income FY2021 −12.65M USD. Net income FY2022 −18.6M USD. Net income FY2023 −7.95M USD. Net income FY2024 −7.68M USD. Net income FY2025 −8.16M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Revenue4.94M USD4.6M USD4.14M USD1.09M USD—
Cost of goods sold3.24M USD3.5M USD2.73M USD545.89K USD—
Gross profit1.71M USD1.1M USD1.4M USD543.55K USD—
Research and development2.85M USD3.22M USD3.73M USD7.28M USD6.62M USD
Selling, general, and administrative6.56M USD5.8M USD5.85M USD6.87M USD5.55M USD
Operating expenses9.62M USD9.24M USD9.78M USD14.34M USD12.17M USD
Interest income156.54K USD721.97K USD652.37K USD123.72K USD16.02K USD
Interest expense373.11K USD———360.35K USD
Depreciation and amortization534.73K USD604.52K USD596K USD511.79K USD149.84K USD
Operating income−7.92M USD−8.13M USD−8.38M USD−13.79M USD−12.17M USD
Net income−8.16M USD−7.68M USD−7.95M USD−18.6M USD−12.65M USD

Company facts updated Aug 24, 2026.

Earnings

EPS beat rate
33%
2 beats, 4 misses, 0 met estimates
Average EPS surprise
-871.31%
6 comparable reports
Latest EPS result
-0.69
Estimate -94.44 · Beat by 99.27%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates10.15-27.3-64.74-102.19Q4 '24MissQ1 '25No estimateQ2 '25No estimateQ3 '25No estimateQ4 '25No estimateQ1 '26No estimateQ2 '26BeatQ3 '26Estimate
Q4 2024, reported Nov 14, 2024: actual -0.542, estimate 0.015, surprise -3619.48%, Miss. Q1 2025, reported Feb 12, 2025: actual -3.64, estimate —, surprise —, Comparison unavailable. Q2 2025, reported May 12, 2025: actual -1.94, estimate —, surprise —, Comparison unavailable. Q3 2025, reported Sep 23, 2025: actual 2.4, estimate —, surprise —, Comparison unavailable. Q4 2025, reported Nov 6, 2025: actual -0.44, estimate —, surprise —, Comparison unavailable. Q1 2026, reported Feb 11, 2026: actual -0.51, estimate —, surprise —, Comparison unavailable. Q2 2026, reported May 6, 2026: actual -0.69, estimate -94.44, surprise +99.27%, Beat. Q3 2026, reported Sep 23, 2026: actual —, estimate -94.44, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates2.42M1.88M1.33M789.13KQ3 '24BeatQ4 '24MissQ1 '25BeatQ2 '25MissQ3 '25MissQ4 '25No estimateQ1 '26No estimateQ2 '26No estimate
Q3 2024, reported Sep 27, 2024: actual 2.31M USD, estimate 1.79M USD, surprise +29.40%, Beat. Q4 2024, reported Nov 14, 2024: actual 901.86K USD, estimate 1.39M USD, surprise -34.98%, Miss. Q1 2025, reported Feb 12, 2025: actual 1.24M USD, estimate 1.13M USD, surprise +10.04%, Beat. Q2 2025, reported May 12, 2025: actual 1.17M USD, estimate 1.49M USD, surprise -21.20%, Miss. Q3 2025, reported Sep 23, 2025: actual 1.29M USD, estimate 1.79M USD, surprise -27.90%, Miss. Q4 2025, reported Nov 6, 2025: actual 1.26M USD, estimate —, surprise —, Comparison unavailable. Q1 2026, reported Feb 11, 2026: actual 1.11M USD, estimate —, surprise —, Comparison unavailable. Q2 2026, reported May 6, 2026: actual 1.26M USD, estimate —, surprise —, Comparison unavailable.

INM news

defenseworld.net

Financial Survey: InMed Pharmaceuticals (NASDAQ:INM) & Reviva Pharmaceuticals (NASDAQ:RVPH)

InMed Pharmaceuticals (NASDAQ: INM - Get Free Report) and Reviva Pharmaceuticals (NASDAQ: RVPH - Get Free Report) are both small-cap healthcare companies, but which is the superior stock? We will compare the two…

Read source
benzinga.com

InMed Pharmaceuticals Merger Partner Raises $200 Million To Boost Migraine Pipeline

Mentari Therapeutics, a privately held biotechnology enterprise dedicated to preventing migraines, has successfully secured an additional $200 million through a new private placement.

Read source
prnewswire.com

Mentari Therapeutics Announces $200 Million Private Placement for Migraine Prevention Pipeline

WALTHAM, Mass., July 22, 2026 /PRNewswire/ -- Mentari Therapeutics, Inc. ("Mentari"), a privately-held biotechnology company developing therapies for migraine prevention, today announced a $200 million private placement…

Read source
seekingalpha.com

Artisan Mid Cap Fund Q2 2026 Performance Review

Artisan Mid Cap Fund portfolio generated strong absolute returns and outpaced the Russell Midcap® Growth Index. Within IT, several semiconductor holdings produced exceptional returns, with multiple positions rising more…

Read source
prnewswire.com

Are ESI, INM, HUN, OLN Obtaining Fair Deals for their Shareholders?

/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws

Read source
newsfilecorp.com

InMed Pharmaceuticals and Mentari Therapeutics Announce Amendment to Merger Agreement and Filing of Registration Statement on Form S-4

Vancouver, British Columbia and San Francisco, California--(Newsfile Corp. - July 6, 2026) - InMed Pharmaceuticals, Inc. (NASDAQ: INM) ("InMed" or the "Company") today announced that it has entered into an amendment (the…

Read source

Corporate actions

Corporate action history

Stock split

Effective Nov 14, 2024

1:20

Stock split

Effective Sep 7, 2022

1:25

Stock split

Effective Jul 6, 2020

1:33

INM peers

Amgen Inc. logo

AMGN

Amgen Inc.

$440.73

+0.32%

Gilead Sciences, Inc. logo

GILD

Gilead Sciences, Inc.

$145.43

-0.47%

Vertex Pharmaceuticals Incorporated logo

VRTX

Vertex Pharmaceuticals Incorporated

$548.21

+0.03%

Intuitive Surgical, Inc. logo

ISRG

Intuitive Surgical, Inc.

$376.96

-0.49%

Sanofi logo

SNY

Sanofi

$45.6371

-0.46%

Regeneron Pharmaceuticals, Inc. logo

REGN

Regeneron Pharmaceuticals, Inc.

$824.47

-1.15%

Continue in GoAI

Research INM

research.disclaimer